New Market Research Report: Global Diabetic Retinopathy Market 2014-2018

DR is defined as an eye disorder that damages the blood vessels of the retina. The retina is the light-sensitive inner surface of the eye which acts as a film for the formation of an image. Long-term diabetes affects the retina as a high blood glucose level can deteriorate and damage the tiny blood vessels in the retina. DR is broadly classified into either non-proliferative DR or proliferative retinopathy. Treatment for DR is dependent on the stage of the disease and is directed at trying to slow or stop the progression of the disease. At present, three types of treatment exist for DR: laser surgery, injection of corticosteroids or anti-VEGF drugs into the eye, and vitrectomy.

Full Report Details at
- http://www.fastmr.com/prod/842597_global_diabetic_retinopathy_market_20142018.aspx?afid=301

TechNavio's analysts forecast the Global DR market will grow at a CAGR of 6.8 percent over the period 2013-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global DR market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various ophthalmic injections and drugs used in the treatment of DR.

TechNavio's report, the Global DR Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global DR market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

* Americas
* EMEA
* APAC

Key Vendors

* Bayer AG
* F. Hoffmann-La Roche Ltd.
* Novartis AG
* Pfizer Inc.
* Regeneron Pharmaceuticals Inc.
* Valeant Pharmaceuticals International Inc.

Other Prominent Vendors

* Abbott Laboratories Ltd.
* Alcon Laboratories Inc.
* Alimera Sciences Inc.
* Allergan Inc.
* Ampio Pharmaceuticals Inc.
* Antisense Therapeutics Ltd.
* Bausch & Lomb Inc.
* BCN Peptides SA
* Boehringer Ingelheim GmbH
* Ferrosan Holding A/S
* iCo Therapeutics Inc.
* Isis Pharmaceuticals Inc.
* LPath Inc.
* Lupin Ltd.
* Novast Laboratories Ltd.
* OPKO Health Inc.
* Parexel International Corp.
* pSivida Corp.
* Quark Pharmaceuticals Inc.
* Sirnaomics Inc.
* Thrombogenics NV
* Torrent Pharmaceuticals Ltd.
* Vitreoretinal Technologies Inc.

Key Market Driver

* Increase in Prevalence of Diabetes.
* For a full, detailed list, view our report.

Key Market Challenge

* Lack of Accurate Diagnosis of the Disease.
* For a full, detailed list, view our report.

Key Market Trend

* Increase in Awareness of DR Treatment.
* For a full, detailed list, view our report.

Key Questions Answered in this Report

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Diabetic Retinopathy Global Clinical Trials Review, H1, 2014
- Proliferative Diabetic Retinopathy (PDR) Global Clinical Trials Review, H1, 2014
- Diabetic Retinopathy - Pipeline Review, H1 2014
- Diabetic Retinopathy - Pipeline Review, H2 2013
- EpiCast Report: Diabetic Retinopathy - Epidemiology Forecast to 2022